Standard Biotools Inc (LAB) Stock Price, Quote & News

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 266 6000

Fax: 650 871 7152

Website: www.standardbio.com

Address:

50 Milk Street, 10th Floor, Boston, United States

OriginalTradeonrumor May. 13 at 6:49 PM

$LAB show me tutes are ensuring the price is at $1 without telling me …I’m pretty sure near 100% off the daily volume are tutes!

0 · Reply

OriginalTradeonrumor May. 13 at 6:23 PM

$LAB back at $1🥳

0 · Reply

OriginalTradeonrumor May. 13 at 5:19 PM

$LAB somebody dumpd to .96—let’s see if they can get it back to .99/$1!

0 · Reply

OriginalTradeonrumor May. 12 at 10:25 PM

$LAB am I the only one watching trading here? There is a clear push to keep this over $1…and it’s no one here doing it 🤣…do you think there might be a reason for that? 🤔

0 · Reply

Jkpga May. 12 at 8:14 PM

$LAB still junk

0 · Reply

GreenPond May. 12 at 2:48 PM

$LAB It’s criminal if someone intentionally keep suppressing the share price below $1 mark. @SEC. Make NO sense that market cap is less than cash at hand.

1 · Reply

GreenPond May. 12 at 5:53 AM

$LAB Info sharing only Look who is holding and accumulating

0 · Reply

GreenPond May. 12 at 5:47 AM

$LAB From Q1 2026 financial results, the CEO said " and our cost savings initiatives are taking hold with a 78% improvement...., reinforcing our path to profitability in 2026." Here he used 'in 2026', which means a guidance that we can achieve profitability before end of 2026. https://investors.standardbio.com/node/20561/pdf

0 · Reply

OriginalTradeonrumor May. 7 at 2:36 PM

$LAB hitting and closing 1.03 is the magic button that gets us to our first leg to 1.10…going to be tough but eventually…if not today we’ll do it in the short term! Let’s see what happens!

0 · Reply

OriginalTradeonrumor May. 7 at 2:17 PM

$LAB ok I added .005🤣

0 · Reply

Standard BioTools Reports First Quarter 2026 Financial Results

2026-02-24T21:17:26.000Z - 2 months ago

Standard BioTools reports Q4 EPS 5c vs (9c) last year

2026-02-24T21:16:44.000Z - 2 months ago

Standard BioTools sees FY26 revenue $80M-$85M, consensus $79.73M

Feb 24, 2026, 4:10 PM EST - 2 months ago

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 10, 2026, 7:00 AM EST - 3 months ago

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

2026-01-30T14:16:09.000Z - 3 months ago

Standard BioTools completes sale of SomaLogic to Illumina

ILMN

Jan 30, 2026, 9:09 AM EST - 3 months ago

Standard BioTools Completes Sale of SomaLogic to Illumina

2026-01-08T12:05:40.000Z - 4 months ago

Standard BioTools sees Q4 revenue from cont. ops. $24M, consensus $18.5M

Jan 8, 2026, 7:00 AM EST - 4 months ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Nov 19, 2025, 11:30 AM EST - 6 months ago

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Nov 10, 2025, 12:15 PM EST - 6 months ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

ILMN

2025-11-05T13:50:39.000Z - 6 months ago

Standard BioTools price target lowered to $1.35 from $1.55 at TD Cowen

Nov 4, 2025, 4:05 PM EST - 6 months ago

Standard BioTools Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 7:00 AM EDT - 7 months ago

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Sep 3, 2025, 9:15 AM EDT - 9 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

ILMN

2025-08-13T10:05:55.000Z - 9 months ago

Standard BioTools downgraded to Hold from Buy at TD Cowen

2025-08-11T20:16:09.000Z - 9 months ago

Standard BioTools reports Q2 EPS (9c), consensus (4c)

2025-08-11T20:15:49.000Z - 9 months ago

Standard BioTools sees FY25 revenue $165M-$175M, consensus $169.13M

Aug 11, 2025, 4:01 PM EDT - 9 months ago

Standard BioTools Reports Second Quarter 2025 Financial Results

2025-08-06T11:30:45.000Z - 10 months ago

Standard BioTools, Precision Health, Singapore launch proteomic collaboration

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

2025-06-23T17:12:37.000Z - 11 months ago

Standard BioTools to sell SomaLogic to Illumina for $350M upfront payment

ILMN

2025-06-23T17:10:18.000Z - 11 months ago

Illumina to acquire SomaLogic for $350M in cash

ILMN

Jun 23, 2025, 7:13 AM EDT - 11 months ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

ILMN

Jun 23, 2025, 7:05 AM EDT - 11 months ago

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

2025-05-30T11:15:44.000Z - 1 year ago

Standard BioTools to host inaugural ‘Proteomics Roundtable’ series

May 30, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

May 6, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings Call Transcript: Q1 2025

2025-05-06T20:16:39.000Z - 1 year ago

Standard BioTools reports Q1 EPS (7c), consensus (4c)

May 6, 2025, 4:01 PM EDT - 1 year ago

Standard BioTools Reports First Quarter 2025 Financial Results

2025-04-24T11:16:19.000Z - 1 year ago

Standard BioTools announces new product innovations at AACR 2025

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Standard BioTools Transcript: KeyBanc Annual Health Care Forum 2025

Mar 3, 2025, 3:10 PM EST - 1 year ago

Standard BioTools Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 4:01 PM EST - 1 year ago

Standard BioTools to Participate in Upcoming Investor Conferences

2025-02-27T09:40:45.000Z - 1 year ago

Standard BioTools downgraded to Sector Weight from Overweight at KeyBanc

Feb 26, 2025, 4:30 PM EST - 1 year ago

Standard BioTools Earnings Call Transcript: Q4 2024

2025-02-26T21:27:29.000Z - 1 year ago

Standard BioTools reports Q4 EPS (9c), consensus (3c)

2025-02-26T21:26:38.000Z - 1 year ago

Standard BioTools sees FY25 revenue $165M-$175M, consensus $186.93M

Feb 26, 2025, 4:01 PM EST - 1 year ago

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Standard BioTools Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 8:00 AM EST - 1 year ago

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 19, 2024, 3:30 AM EST - 1 year ago

Standard BioTools Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 4:15 PM EST - 1 year ago

Standard BioTools Transcript: UBS Global Healthcare Conference 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings Call Transcript: Q3 2024

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Standard BioTools Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Standard BioTools Transcript: UBS Genomic Medicine Summit

Aug 13, 2024, 9:00 AM EDT - 1 year ago

Standard BioTools Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Jul 31, 2024, 4:30 PM EDT - 1 year ago

Standard BioTools Earnings Call Transcript: Q2 2024

Jul 31, 2024, 4:02 PM EDT - 1 year ago

Standard BioTools Announces Senior Leadership Changes

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 8:01 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024

Jun 5, 2024, 2:30 PM EDT - 2 years ago

Standard BioTools Transcript: Jefferies Global Healthcare Conference

May 28, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers

May 20, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2024, 4:30 PM EDT - 2 years ago

Standard BioTools Earnings Call Transcript: Q1 2024

May 8, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:01 AM EDT - 2 years ago

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

Apr 3, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Mar 19, 2024, 10:30 AM EDT - 2 years ago

Standard BioTools Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 18, 2024, 8:12 AM EDT - 2 years ago

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Mar 6, 2024, 1:30 PM EST - 2 years ago

Standard BioTools Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:30 PM EST - 2 years ago

Standard BioTools Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:01 PM EST - 2 years ago

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Feb 7, 2024, 8:30 AM EST - 2 years ago

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Jan 8, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Jan 5, 2024, 8:46 AM EST - 2 years ago

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Jan 4, 2024, 10:23 PM EST - 2 years ago

Standard BioTools Stockholders Approve Merger with SomaLogic

Jan 4, 2024, 9:44 PM EST - 2 years ago

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

Dec 31, 2023, 2:10 PM EST - 2 years ago

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Dec 29, 2023, 7:10 PM EST - 2 years ago

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

Dec 29, 2023, 5:04 PM EST - 2 years ago

Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

Dec 28, 2023, 4:16 PM EST - 2 years ago

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

Dec 22, 2023, 8:11 PM EST - 2 years ago

Tikvah Management Announces Intention to Vote against Somalogic's Proposed Merger with Standard BioTools

Dec 22, 2023, 8:00 PM EST - 2 years ago

Madryn Asset Management Reiterates Alternative Path to SomaLogic's Value-Destructive Proposed Merger with Standard BioTools

OriginalTradeonrumor May. 13 at 6:49 PM

$LAB show me tutes are ensuring the price is at $1 without telling me …I’m pretty sure near 100% off the daily volume are tutes!

0 · Reply

OriginalTradeonrumor May. 13 at 6:23 PM

$LAB back at $1🥳

0 · Reply

OriginalTradeonrumor May. 13 at 5:19 PM

$LAB somebody dumpd to .96—let’s see if they can get it back to .99/$1!

0 · Reply

OriginalTradeonrumor May. 12 at 10:25 PM

$LAB am I the only one watching trading here? There is a clear push to keep this over $1…and it’s no one here doing it 🤣…do you think there might be a reason for that? 🤔

0 · Reply

Jkpga May. 12 at 8:14 PM

$LAB still junk

0 · Reply

GreenPond May. 12 at 2:48 PM

$LAB It’s criminal if someone intentionally keep suppressing the share price below $1 mark. @SEC. Make NO sense that market cap is less than cash at hand.

1 · Reply

GreenPond May. 12 at 5:53 AM

$LAB Info sharing only Look who is holding and accumulating

0 · Reply

GreenPond May. 12 at 5:47 AM

0 · Reply

OriginalTradeonrumor May. 7 at 2:36 PM

$LAB hitting and closing 1.03 is the magic button that gets us to our first leg to 1.10…going to be tough but eventually…if not today we’ll do it in the short term! Let’s see what happens!

0 · Reply

OriginalTradeonrumor May. 7 at 2:17 PM

$LAB ok I added .005🤣

0 · Reply

OriginalTradeonrumor May. 7 at 2:15 PM

$LAB I’ll admit …I’ve been buying so much today I pushed it over $1 🤣…so may go back down …but I am putting another 10,000 shares at .98 🙂 Let’s see what happens!

0 · Reply

BIG_BULL_CORPORATION May. 7 at 4:10 AM

$LAB $RAVE.X $INDEX.X

0 · Reply

WHO905 May. 6 at 8:51 PM

$LAB I think the first M&A announcement will come quickly. One strong cash and stock deal could change the valuation and Wall St. outlook on this company in a second.

0 · Reply

WallStreetWoof May. 6 at 3:13 PM

$LAB Book value is $1.10 per Y! With great earnings report, LAB should be trading at least ~$1.5ish imho

0 · Reply

WHO905 May. 6 at 1:39 PM

$LAB Theives picking on a dollar stock. No way this should be pinned under a buck.

0 · Reply

OriginalTradeonrumor May. 6 at 1:27 PM

$LAB don’t know what will happen today…but it will be volatile!! 🤣 Let’s see what happens!

0 · Reply

beckphan08 May. 6 at 12:02 PM

$LAB just voted in the yearly shareholders poll and are they trying to dilute this more with employee shareholder issuance 1.2 million shares !?

0 · Reply

GreenPond May. 6 at 4:04 AM

$LAB From my research: Peapod Lane Capital LLC recently filed 13F on 5/2/2026 and they bought more than 2 million fresh shares. https://fintel.io/so/us/lab/peapod-lane-capital-llc-3217 If you don't know Peapod Lane Capital LLC yet, look at their homepage. https://peapodlane.com/ "Peapod invests in deeply out-of-favor companies at a substantial discount to traditional valuation metrics. We target companies trading at a discount to liquidation or replacement value. Peapod focuses on US-listed micro and nano-cap securities."

0 · Reply

MoneyTree82 May. 6 at 2:53 AM

$LAB isn’t this massively undervalued? Market cap of 382 million and we have 550 million in cash or investments And the company is suppose to make 80-85 million this year??? What is going on shouldn’t this be at least 1.35 or more?? $NDAQ

0 · Reply

WHO905 May. 6 at 12:27 AM

$LAB Great numbers. Incredibly undervalued. Company could easily be trading at $1B. It is very unfortunate that we are not. Hopefully, onwards and upwards from here!

0 · Reply

OriginalTradeonrumor May. 5 at 8:16 PM

$LAB loving this ….my guess is near term PR with update Let’s see what happens!

1 · Reply

MoneyTree82 May. 5 at 6:28 PM

$LAB Undervalued massively Nothing has changed since this was $1.50-1.60 Cash on hand is more than the current market cap! And the company has reoccurring revenue! No brainer $NDAQ $SPY

0 · Reply

Market Cap	386.46M
Revenue (ttm)	85.33M
Net Income (ttm)	-74.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-87.78%
Debt to Equity Ratio	0.00

Volume	1,908,189
Avg Vol	2,722,524
Day's Range	N/A - N/A
Shares Out	390.37M
Stochastic %K	86%
Beta	1.32
Analysts	Sell
Price Target	$1.55